文献速递前列腺癌

多机构前瞻性试验证实无创血液检测在非裔美国男性中保持预测价值

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
PubMed 文献 · J Urol · 2017-12-06

这项多机构前瞻性研究纳入8个退伍军人事务医疗中心的366名拟行前列腺穿刺男性,其中205名(56%)为非裔美国人。4Kscore检测预测Grade Group 2或以上前列腺癌的AUC为0.81,优于基于年龄、直肠指检和PSA的基础模型(AUC 0.74,p<0.01),且在非裔与非非裔男性间无显著差异(0.80 vs 0.84,p=0.32)。

要点

  • 4Kscore预测GG2+前列腺癌AUC 0.81,优于基础模型AUC 0.74(p<0.01)。
  • 非裔与非非裔男性检测性能无显著差异(AUC 0.80 vs 0.84,p=0.32)。
  • 4Kscore预测风险与观察到的GG2+风险高度吻合。

核心结论

  • 4Kscore检测能准确预测侵袭性前列腺癌,在非裔和非非裔美国男性中均可用于穿刺决策。

研究设计与样本

  • 多机构前瞻性研究,纳入8个退伍军人事务医疗中心因前列腺穿刺转诊的366名男性,其中205名(56%)为非裔美国人。

主要发现

  • 366名男性中131名(36%)活检检出Grade Group 2或以上前列腺癌。
  • 4Kscore预测GG2+前列腺癌的AUC为0.81,基础模型(年龄、直肠指检、PSA)AUC为0.74,差异有统计学意义(p<0.01)。
  • 决策曲线分析显示4Kscore临床 usefulness 高于基础模型。
  • 4Kscore预测风险与观察到的GG2+前列腺癌风险高度吻合。
  • 非裔与非非裔男性检测性能无显著差异(AUC 0.80 vs 0.84,p=0.32),且4Kscore在各组中均优于基础模型。

关键数值与推荐

  • 主要结局为活检检出Grade Group 2或以上前列腺癌。
  • 4Kscore预测GG2+前列腺癌AUC 0.81 vs 基础模型0.74(p<0.01)。
  • 非裔男性AUC 0.80 vs 非非裔男性0.84(p=0.32)。

临床怎么用

  • 在非裔和非非裔美国男性中,4Kscore可准确预测侵袭性前列腺癌,辅助穿刺决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. MATERIALS AND METHODS: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. RESULTS: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. CONCLUSIONS: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Punnen S, Freedland SJ, Polascik TJ, et al. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. J Urol. 2017. PMID: 29223389. doi:10.1016/j.juro.2017.11.113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。